borgal vet 200 mg/ ml / 40 mg/ ml
ceva santé animale s.a - sulfadoksin / trimetoprim - injeksjonsvæske, oppløsning - 200 mg/ ml / 40 mg/ ml
equibactin vet. 250 mg/ g / 50 mg/ g
dechra regulatory b.v. - sulfadiazin / trimetoprim - pulver - 250 mg/ g / 50 mg/ g
paracetduo 500 mg / 65 mg
weifa as - paracetamol / koffein - brusetablett - 500 mg / 65 mg
nazaren 1 mg/ ml
weifa as - xylometazolinhydroklorid - nesespray, oppløsning - 1 mg/ ml
nazaren 0.5 mg/ ml
weifa as - xylometazolinhydroklorid - nesespray, oppløsning - 0.5 mg/ ml
norodine vet 58 mg/ g / 288.3 mg/ g
scanvet animal health a/s - trimetoprim / sulfadiazin - oralpasta - 58 mg/ g / 288.3 mg/ g
besremi
aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi er indisert som monoterapi hos voksne for behandling av polycythaemia vera uten symptomatisk splenomegaly.
pegasys
pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om å innlede behandling i paediatric pasienter se kapittel 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for hepatitt c-virus (hcv) genotypen bestemt aktivitet, se kapittel 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når du bestemmer deg for å starte behandling i barndommen, er det viktig å vurdere vekst hemming indusert ved kombinasjonsbehandling. den reversibilitet av vekst hemming er usikker. beslutningen om å behandle bør gjøres på en sak til sak-basis (se kapittel 4.
cernevit
baxter medical ab - retinylpalmitat / kolekalsiferol / tokoferol alfa / askorbinsyre / tiamin / riboflavinnatriumfosfathydrat / pyridoksinhydroklorid / cyanokobalamin / folsyre / pantotensyre / biotin / nikotinamid - pulver til injeksjons-/infusjonsvæske, oppløsning - 3500 ie / 220 ie / 11.2 ie / 125 mg / 3.51 mg / 4.14 mg / 4.53 mg / 0.006 mg / 0.414 mg / 17.25 mg / 0.069 mg / 46 mg
equibactin vet 66.7 mg/ g / 333.3 mg/ g
le vet b.v. - trimetoprim / sulfadiazin - oralpasta - 66.7 mg/ g / 333.3 mg/ g